Document:

LICENSE AGREEMENT FROM IBC TO EMPYREAN

                  (for sales of Licensed Products in the U.S.)
<PAGE>
                     LICENSE AGREEMENT FROM IBC TO EMPYREAN

This License Agreement (the "Agreement") made as of the 9th day of August,  2000
("the  Effective  Date")  by  and  among  INTERNATIONAL  BIOSCIENCE  CORPORATION
("IBC"),  a Florida  corporation,  having an office at 777 South Flagler  Drive,
Phillips Point Building,  East Tower, Suite 909, West Palm Beach, Florida 33401,
and EMPYREAN BIOSCIENCE,  INC.  ("Empyrean"),  a Wyoming corporation,  having an
office at 23800 Commerce Park Road, Suite A, Cleveland , Ohio 44122;

                                WITNESSETH THAT:

     WHEREAS,  Empyrean  desires  to acquire an  exclusive  license  from IBC to
purchase the Licensed Products (as defined below) and to sell and distribute the
Licensed Products in the United States;

     WHEREAS, IBC (or its predecessors) entered into a Distributorship Agreement
dated March 20, 1997 with Prevent-X,  Inc. ("Prevent-X"),  pursuant to which IBC
granted Prevent-X the exclusive right to distribute and sell Lotion Products (as
defined  below)  in  the  United  States  (the  "United  States  Distributorship
Agreement");

     WHEREAS, Empyrean (its predecessor or subsidiary) entered, with the consent
and  novation  of IBC,  into a  Sub-License  Agreement  dated July 20, 1998 with
Prevent-X  pursuant  to which  Prevent-X  appointed  Empyrean  as its  exclusive
sub-licensee  and assigned all its rights and delegated all its duties under the
United  States  Distributorship   Agreement  to  Empyrean  (the  "United  States
Sub-License Agreement");
<PAGE>
     WHEREAS,  Empyrean,  as of the  Effective  Date,  has been and continues to
purchase and sell Lotion Products under the United States Sub-License Agreement;

     NOW,  THEREFORE,  in  consideration  of the  premises  and  of  the  mutual
undertakings   hereinafter   set  forth,   and  for  other  good  and   valuable
consideration, IBC and Empyrean hereby agree as follows:

     1. DEFINITIONS

     In this Agreement the following  terms shall have the meanings  hereinafter
specified:

     (a) An "Approved  Manufacturer" shall mean those manufacturers selected and
approved by IBC-Empyrean LLC for manufacture of the Licensed Products.

     (b) An "Approved  Packager" shall mean those packaging  companies  selected
and approved by IBC-Empyrean LLC for packaging of the Licensed Products.

     (c) "Derivative  Products" shall mean products hereinafter developed by IBC
having an  effective  amount of  Formulation  therein,  and being of a different
product category than those Licensed Products currently being manufactured.

     (d)  "Formulation"  shall  mean  the  proprietary   formulation  (including
manufacturing  technology and processes) comprising  Benzalkonium Chloride as an
active  ingredient  with  Octoxynol 9 (and  others)  invented and created by Dr.
David  Thornburgh  and  exclusively  owned  by IBC  known  as the  GEDA  line of
products.

     (e) "Gel Product" shall mean the spermicide and  microbicide  contraceptive
gel product  embodying the  Formulation  presently  being developed by IBC, also
known as the GEDA Plus product, designed to prevent the transmission of sexually
transmitted  diseases  including,  but not  limited  to,  gonorrhea,  chlamydia,
syphilis,  Trichomonas,  herpes  I and  II  and  HIV,  and  which  is  presently

                                        2
<PAGE>
undergoing the appropriate and necessary United States  governmental  regulatory
compliance  process to permit  Empyrean  to include  such  product as a Licensed
Product hereunder.

     (f) "Licensed  Products" shall mean products having an effective  amount of
the  Formulation  therein  and  having all  necessary  government  approval  for
commercialization,  including,  but not  limited  to, the Lotion  Products,  Gel
Product and any Derivative Products hereinafter developed by IBC.

     (g)  "Lotion  Products"  (also  known as GEDA  Lotion)  shall mean the hand
sanitizing  lotion presently being  manufactured for Empyrean by Canadian Custom
Packaging  and sold by  Empyrean  as a Licensed  Product,  and  presently  being
marketed by Empyrean under appropriate and necessary United States  governmental
regulatory compliance.

     (h) "Net  Sales"  shall  mean the  total  of  gross  sales of the  Licensed
Products by Empyrean to a third  party,  at the invoice  selling  price,  net of
normal and reasonable cash, trade and quantity discounts and returns for credit,
and  without   deductions   for  costs  incurred  in   manufacturing,   selling,
distributing or advertising or for uncollectable accounts.

     (i) "Territory" shall mean the United States of America and its possessions
and territories.

     2. REPRESENTATIONS

     IBC represents as follows:

     (a) IBC has the right and authority (i) to enter into this  Agreement,  and
(ii) to grant the License as defined in Section 5 below.

     (b) With the exception of the United States  Distributorship  Agreement and
with the  exception of any rights or claims to the  Formulation  asserted by, on
behalf  of,  or  through  Optima  Holding  Company  and/or  Mercury   Technology

                                        3
<PAGE>
Corporation in Cases No. 98-11552 CA (09), 98-15352 CA (25) and 98-23428 CA (23)
now pending in the Circuit  Court of  Miami-Dade  County  Florida,  and Case No.
00-8300-CIV-Dimitrouleas,  now pending in the United States  District  Court for
the Southern District of Florida, IBC represents that:

          (i) it owns all right,  title and  interest to and in the  Formulation
free of all liens and encumbrances thereto,

          (ii) IBC has executed no agreement in conflict herewith,

          (iii) IBC has not granted to any other person,  firm,  corporation  or
entity any right or license to make,  have made,  use,  sell or  distribute  the
Formulation or the Licensed Products in the Territory; and

          (iv) To the  best  of  IBC's  knowledge,  the  Formulation  for use in
connection  with the  Licensed  Products  does not infringe any patents of third
parties,  nor is IBC aware of any  claims  by third  parties  that the  Licensed
Products infringe any patent of third parties. Empyrean represents as follows:

     (c) Empyrean has the right and authority to enter into this Agreement.

     (d) Empyrean has executed no agreement in conflict herewith.

     (e)  Empyrean  has  granted  no rights to make,  have  made,  use,  sell or
distribute  the  Formulation  or the Licensed  Products in the  Territory to any
sublicensee or distributor.

     3. CONFIDENTIALITY

     (a)  In   consideration  of  this  Agreement  and  in  the  course  of  its
fulfillment,  and solely for the mutual  benefit of the parties  hereto,  IBC or
Empyrean  (their  predecessors,  subsidiaries  or affiliates)  may send (or have

                                        4
<PAGE>
previously  sent) or supply (or have  previously  supplied) the other party with
confidential  information  with regard to the  Formulation,  Licensed  Products,
pricing or marketing strategy.  The information may be (or may have been) marked
"Company  Proprietary",  or "Company  Confidential"  or another  similar  manner
indicating its  confidentiality.  This  information may pertain to such items as
price lists, financial information,  contracts,  product information,  plans and
design   documentation   relating  to  IBC's  business  or  Empyrean's  business
("Business  Information")  and may also pertain to such items as the Formulation
or the  manufacturing  process used in  connection  with the  Licensed  Products
("Formulation Information").  Each party hereto agrees to keep any such Business
Information  confidential  for a period of not less than five (5) years from the
date of termination of this Agreement,  and agrees to keep any such  Formulation
Information confidential in perpetuity.

     (b)  Each  party  further  assumes  liability  hereunder  for the  actions,
statements   and   representations   of   its   employees,   officers,   agents,
representatives and sublicensees; and agrees to inform them of the provisions of
this Agreement and enforce its provisions against each of them.

     (c) Each of the parties  mutually  agree that the rights  protected by this
Article are unique and not  adequately  protected  or  compensated  for by money
damages.  In the event of a material breach or threatened material breach of the
provisions  of this  Section,  IBC or  Empyrean  shall be entitled to enjoin the
other party from use and  dissemination  of any and all the respective  parties'
confidential information.

     4. PROTECTION OF THE FORMULATION

     (a)  Empyrean   acknowledges  that  the  Formulation  is  confidential  and
proprietary  information  owned by IBC and that it does not have any right in or
to the  Formulation  except as provided in Section 5. Empyrean agrees to protect

                                        5
<PAGE>
the  confidentiality  of the  Formulation in accordance with Section 3 above and
further  agrees to make no  disclosure  of the  Formulation  to any third  party
should Empyrean know or come to know the Formulation.

     5. EXCLUSIVE LICENSE FROM IBC TO EMPYREAN

     (a) IBC grants to Empyrean an exclusive right and license in the Territory:

          (i) to purchase from an Approved Manufacturer Licensed Products and/or
products  containing the Formulation for packaging into a Licensed Product by an
Approved Packager; and

          (ii) to use, have used, sell and have sold the Licensed Products.

     (b) Empyrean  agrees to use reasonable  commercial  efforts,  and to expend
within five (5) years of  executing  this  Agreement,  if  necessary,  up to ten
million United States dollars (US$10,000,000) to market the Licensed Products in
the Territory during the term of this Agreement.

     6. EXCLUSIVE LICENSE

         (a) The License  from IBC to  Empyrean,  as defined in Section 5 above,
shall be exclusive  during the term of this Agreement.  IBC covenants and agrees
not  to  sell  the  Formulation  or  Licensed  Products  to  any  person,  firm,
partnership,  corporation  or other entity other than Empyrean in the Territory,
and agrees not to sell the Formulation or Licensed Products to any person, firm,
partnership,  corporation or other entity that sells Licensed  Products into the
Territory,  and shall not grant any right or appoint any distributor or licensor
other than Empyrean to purchase,  sell, use, market, offer to sell or distribute
the  Formulation  or the Licensed  Products in the  Territory.  In the event IBC
breaches the provisions of this Section,  Empyrean may, in addition to its other

                                        6
<PAGE>
rights,  including damages, enjoin any such breach upon thirty (30) days written
notice specifying the nature of such breach,  unless,  within such 30-day period
IBC  discontinues  such breach and provides a written notice to Empyrean of such
discontinuance  together  with the  identification  of the steps taken by IBC to
discontinue such breach.

     7. ROYALTIES

     (a) For the Term of this  Agreement,  Empyrean  shall  pay to IBC a Royalty
which shall be computed as five percent (5%) of Empyrean's Net Sales of Licensed
Products to any third party.

     (b) Empyrean  shall pay all Royalties to IBC quarterly,  within  forty-five
(45) days after the end of each calendar quarter.

     (c) IBC acknowledges that Empyrean's  obligation to pay royalties to IBC is
based upon Empyrean's  exclusive  right to sell,  offer for sale, and distribute
Licensed  Products in the Territory.  If, during the Term of this  Agreement,  a
third party not a sublicensee,  distributor or joint venturer of Empyrean sells,
offers  for sale,  or  distributes  Licensed  Products  in the  Territory  which
products originate in whole or in part from IBC ("Third Party Sales"),  Empyrean
shall  promptly  notify IBC in writing of such Third Party Sales,  including the
name of such Third Party and the type of Licensed  Product  being sold,  offered
for sale or  distributed  in  accordance  with the terms set forth in Section 19
below.  After formal notice of Third Party Sales from Empyrean to IBC,  Empyrean
shall also have the right seek a preliminary injunction against IBC or any third
party to enjoin any such Third Party Sales upon thirty (30) days written  notice
specifying  the nature of such Third  Party  Sales,  unless,  within such 30-day
period  such  Third  Party  Sales  discontinue.  If  it is  established  through
arbitration  that such Third Party Sales are the fault,  in whole or in part, of
IBC then  Empyrean  shall have the right to cease  paying  Royalties  thereafter
incurred by Empyrean until such Third Party Sales cease.

                                        7
<PAGE>
     (d) If, during the Term of this Agreement,  Empyrean is forced or otherwise
obligated  to pay a royalty  to a third  party for sale or  distribution  of the
Licensed  Products in the  Territory  by reason of such third  party's  claim of
patent or trade secret rights in or to the Formulation or the Licensed Products,
any and all Royalties thereafter incurred by Empyrean under this Agreement shall
be reduced by an amount equal to such royalties paid to such third party.

     8. REPORTING AND RECORD KEEPING

     (a) Within  forty-five  (45) days after the end of each  calendar  quarter,
irrespective  of whether any Net Sales have been made or whether any sum is then
due to IBC,  Empyrean  shall  deliver to IBC via  regular  mail a  complete  and
accurate written  statement  setting forth the amount of Licensed Products sold,
the gross price at which such  Licensed  Products  were sold,  the amount of any
discount or allowances  given  consistent with the terms of this Agreement,  the
credit for Licensed Products allowed to be returned and other deductions allowed
herein to compute Net Sales in specific  detail,  so as to  reasonably  allow an
audit of underlying  documents,  together  with  Empyrean's  calculation  of the
amount of royalties then due IBC for the period covered by such report.

     (b)  Empyrean  shall  keep or  cause  to be  kept  accurate,  complete  and
up-to-date  books of accounts  separately  stating by clear means records of all
sales of the Licensed Products  including records pertaining to invoiced amounts
by  customer  and  records   pertaining  to  all  freight  charges,   discounts,
allowances,  and returns allowed by Empyrean. Such books and records of accounts
shall  reflect  that a sale of the  Licensed  Products  shall be  deemed to have
occurred as of the date such  Licensed  Products  were  invoiced  to  Empyrean's
customers.

                                        8
<PAGE>
     (c) IBC or its authorized  representatives  shall have the right, once each
calendar  year,  to inspect all records of Empyrean with respect to the Licensed
Products  and to make  copies of said  record  utilizing  Empyrean's  facilities
without charge and shall have free and full access thereto on reasonable  notice
during the normal business hours of Empyrean.  In the event that such inspection
or audit reveals an  underpayment  by Empyrean  under this  Agreement,  Empyrean
shall  immediately  pay to IBC the balance of all such  amounts  found to be due
pursuant to such audit or inspection together with interest thereon at the "best
commercial  customer"  rate at the Bank of America,  plus six  percent  (6%) per
annum from the date such amounts  first became due to IBC until all such amounts
have been paid in full. Further, if such inspection or audit discloses that, for
the annual period reviewed or audited, Empyrean has underpaid or understated its
obligation  under this Agreement by twenty percent (20%) or more,  then Empyrean
shall also pay three times the reasonable  professional  fees of the independent
representatives  (such as auditor  and  attorneys'  fees)  engaged to conduct or
review such inspection or audit.

     9. MODIFICATION OF THE FORMULATION

     (a) Neither IBC nor Empyrean shall alter,  modify or change the Formulation
for use in the Licensed  Products in the Territory  without first  obtaining the
written approval of IBC-Empyrean LLC.

     10. THE GEL PRODUCT

     (a) IBC  covenants  and agrees to use its best  efforts to take any and all
required  action to seek and secure the  approval of the United  States Food and
Drug  Administration  (the "USFDA") to manufacture,  distribute and sell the Gel
Product,  provided,  however,  that Phase III data shows statistics that clearly
demonstrate the efficacy of the Gel Product.

                                        9
<PAGE>
     (b) IBC further  covenants and agrees to expend,  if  necessary,  up to ten
million  United States  dollars  (US$10,000,000)  in  connection  with the USFDA
approval.  For the  avoidance  of doubt,  IBC shall not be required to spend ten
million United States dollars  (US$10,000,000)  for such clinical  trials if the
clinical trials can be successfully conducted for a lesser amount. IBC agrees to
prepare and  conduct  all such  clinical  trials,  and to prepare all  necessary
materials  required in order to achieve approval from the applicable  regulatory
bodies  for the Gel  Product,  in such a way as to  ensure  that  such  clinical
trials,  the results of such clinical trials and/or all materials  produced as a
result of or in connection with achieving  regulatory  approval shall be in such
condition  so as to be  admissible  and  acceptable  to the  USFDA and any other
regulatory  agencies in the United States  required to permit the Gel Product to
be sold in the United States.

     (c) IBC agrees to use its best  efforts to  commence  the  appropriate  and
necessary  governmental  regulatory  approvals  to market the Gel Product in the
United States as preventing the transmission of chlamydia,  gonorrhea, syphilis,
Trichomonas,  herpes I and II  within  twelve  (12)  months  of the date of this
Agreement,  provided, however, that Phase III data shows statistics that clearly
demonstrate the efficacy of the Gel Product.

     (d) IBC agrees to use its best  efforts to  commence  the  appropriate  and
necessary  governmental  regulatory  approvals  to market the Gel Product in the
United  States as  preventing  the  transmission  of HIV within twenty four (24)
months of the date of this  Agreement,  provided,  however,  that Phase III data
shows statistics that clearly demonstrate the efficacy of the Gel Product.

                                       10
<PAGE>
     11. TERM

     (a) The term of this Agreement  shall begin on the Effective Date and shall
continue for a period of ten (10) years (the "Initial Term").

     (b) This Agreement shall be automatically  renewed at the conclusion of the
Initial Term, and each subsequent Additional Term, if applicable, for Additional
Terms of ten (10) years, unless terminated in accordance with Section 12 below.

     12. TERMINATION

     (a) IBC shall  have the right to  terminate  this  Agreement  upon  written
notice to  Empyrean  at least  sixty (60) days prior to the end of any  calendar
year, in the event that Empyrean,  its affiliates and/or  distributors,  sell no
Licensed Products in the Territory for a period of two (2) years.

     (b)  In  the  event  that  Empyrean  otherwise   materially  breaches  this
Agreement,  IBC's sole remedy shall be to seek specific performance by filing an
appropriate  action in  arbitration,  in the event  Empyrean  fails to cure such
breach within sixty (60) days after  receipt of written  notice of such material
breach.

     (c) If, within the first two years of this Agreement, Empyrean fails to pay
any Royalties  with respect to a calendar  quarter for which  Royalties are due,
IBC's  sole  remedy  shall be the right to bring an action  in  arbitration  for
payment of such  Royalties,  plus  interest at the prime  interest rate plus 6%,
plus  attorneys  fees,  in the event  Empyrean  fails to cure such breach within
sixty (60) days after receipt of written notice of such breach.

     (d) If, within the third, fourth and fifth year of this Agreement, Empyrean
fails  to pay any  Royalties  with  respect  to a  calendar  quarter  for  which
Royalties  are due, IBC shall,  in addition to the remedies set forth in Section

                                       11
<PAGE>
12 (c)  above,  have the right to  convert  Empyrean's  exclusive  license  to a
non-exclusive  license,  in the event  Empyrean fails to cure such breach within
sixty (60) days after receipt of written notice of such breach.

     (e) If, after the fifth year of this  Agreement,  Empyrean fails to pay any
Royalties  with respect to a calendar  quarter for which  Royalties are due, IBC
shall,  in addition to the  remedies set forth in Sections 12 (c) and (d) above,
have the right to terminate this Agreement,  in the event Empyrean fails to cure
such  breach  within  thirty (30) days after  receipt of written  notice of such
breach.  IBC shall not be obligated  to arbitrate  its right to any remedy under
this subsection 12(e).

     13. PRESS RELEASES

     (a) IBC and Empyrean  each agree that, in the event either party desires to
issue a press release that refers to the other party by name,  the party issuing
the press release shall, in advance,  submit a copy of such press release to the
other  party  for the  other  party's  approval,  which  approval  shall  not be
unreasonably   withheld;   provided,   however,   that  the  foregoing  approval
requirement  shall not apply in such  circumstances  where a party shall, on the
advice  of  counsel,  issue a press  release  in order to  comply  with any then
applicable  Federal or state  securities law disclosure  requirement.  The other
party  shall have two (2)  business  days to object to such press  release.  The
failure of the other party to object,  or approve,  within two (2) business days
will be deemed by the issuing party as an approval of the press release.

     14. NO PARTNERSHIP or JOINT VENTURE

     (a) Nothing  herein  contained  shall be construed so as to constitute  the
parties  hereto as  partners  or as joint  venturers,  or either as agent of the
other, and neither IBC nor Empyrean shall have the power to obligate or bind the
other in any manner whatsoever.

                                       12
<PAGE>
     15. GENERAL INDEMNIFICATION

     (a) Empyrean agrees

          (i) to assume the defense of any suit brought  against IBC arising out
of Empyrean's packaging, sale, use or distribution of the Licensed Products, and

          (ii)  to  indemnify  IBC  against  any  money  damages  and/or  costs,
including  reasonable  attorneys  fees,  provided  that  (a)  Empyrean  is given
exclusive  control of the defense of such suit and all negotiations  relative to
the  settlement  thereof,  (b) IBC promptly  informs  Empyrean in writing of any
claims for which  Empyrean  has assumed  responsibility  hereunder,  and (c) the
liability  claim shall not have arisen because of wrongful or negligent  conduct
by IBC.

     (b) IBC agrees

          (i) to assume the defense of any suit brought against Empyrean arising
out of a claim  against  Empyrean for any personal  injury,  property  damage or
products  liability  based on the  Formulation,  and/or  based  upon  any  claim
asserted  against any Licensed  Product  label,  Trade Dress or  advertising  or
promotional material that is required and approved by IBC, and

          (ii) to indemnify  Empyrean  against any money  damages  and/or costs,
including  reasonable  attorneys fees,  provided that (a) IBC is given exclusive
control  of the  defense  of such  suit  and all  negotiations  relative  to the
settlement  thereof,  (b) Empyrean promptly informs IBC in writing of any claims
for which IBC has assumed responsibility  hereunder, and (c) the liability claim
shall not have arisen because of wrongful or negligent conduct by Empyrean.

                                       13
<PAGE>
     16. INSURANCE

     (a) IBC and Empyrean agree to maintain at their own expense,  in full force
and effect, at all times during which Licensed Products are being sold and used,
products liability  insurance with limits of liability of at least $5,000,000.00
per  accident  or  occurrence  with  respect to the  Licensed  Products,  with a
recognized and responsible  insurance  carrier duly and/or properly licensed and
reasonably  acceptable to each party.  IBC agrees that,  upon written  notice to
IBC, IBC will raise such limits of liability to meet or exceed limits maintained
by Empyrean in the future. Each party shall be named as an additional insured on
the others'  policy.  Such insurance  shall be in such form or duration as shall
insure against all accidents or occurrences  occurring at all times during which
Licensed  Products are being sold and used  regardless  of when a claim shall be
made. Such insurance shall insure and be for the benefit of Empyrean and IBC and
its officers and directors (same  hereinafter  referred to as "coinsured"),  and
IBC shall  provide for at least  thirty (30) days prior,  written  notice to all
"co-insureds"  and  Empyrean of the  cancellation  or  substantial  modification
thereof. The maintenance of such insurance coverage shall not excuse or take the
place of any of IBC's other obligations. Certificates of such insurance shall be
furnished  to all  co-insureds  within  thirty  (30)  days  of the  date of this
Agreement and annually thereafter for the term of this Agreement.

     17. APPLICABLE LAW

     (a) This  Agreement,  its terms and conditions  and all business  conducted
hereunder  shall be  governed  and  interpreted  under  the laws of the State of
Florida,  without  regard  to  conflict  of laws  provisions.  The  venue of any
arbitration  between the parties arising from or related to this Agreement shall
be in either  Miami-Dade  County or Palm Beach County,  Florida.  Any litigation

                                       14
<PAGE>
arising from or related to this  Agreement  shall be brought  exclusively  in an
appropriate  state or federal court in  Miami-Dade  County or Palm Beach County,
Florida, and the parties waive any right to challenge such venue.

     (b)  Except as agreed  to in  Sections  3, 4 and 6 above,  and  except  for
actions  brought  for  wrongful  termination  or to  seek  termination  of  this
Agreement, if any disagreement arises regarding the interpretation of any points
of the Agreement or any other point not covered herein or any claims for damages
or specific performance,  the disagreement,  upon request of either party hereto
delivered in writing to the other party, shall be resolved by arbitration before
a single  arbitrator in accordance with the commercial  rules and procedures set
forth by the  American  Arbitration  Association.  The  prevailing  party in any
litigation  or  arbitration  brought under this  Agreement  shall be entitled to
recover reasonable attorney's fees and costs.

     (c) In the  event  any  provision  of this  Agreement  shall  be held to be
invalid,  illegal or  unenforceable,  the  remaining  terms shall remain in full
force and effect,  to effectuate  this Agreement in accordance  with its intent.
Headings, title and subtitles of this Agreement are for convenience of reference
only and are not to be considered in construing the terms of this Agreement.

     18. SOLE AND COMPLETE AGREEMENT

     (a) This  Agreement  is the sole and  complete  statement of the parties of
their rights and  obligations  with respect to the subject matter  hereof.  This
Agreement is an  integrated  agreement and replaces and  supersedes  any and all
previous obligations and agreements between the parties,  their predecessors and
subsidiaries, both oral and written. The Parties hereto recognize and agree that
no  representations  or  warranties  have been made  except as set forth in this

                                       15
<PAGE>
Agreement. Except as may otherwise be expressly provided herein, by signing this
Agreement  the parties  expressly  release each other,  their  predecessors  and
subsidiaries from any and all existing  obligations that pre-date this Agreement
as if such obligations  have been fully performed and satisfied.  Any amendments
to this Agreement shall be in writing and executed by both parties hereto.

     19. NOTICES

     (a)  All  notices,  requests,  demands,  instructions,  consents  or  other
communications  required or permitted to be given under this Agreement  shall be
in  writing  and  shall be  deemed  to have  been  duly  given if (i)  delivered
personally,  (ii) mailed  postage  prepaid by  certified  mail,  return  receipt
requested,  (iii)  sent  by a  nationally  recognized  express  courier  service
requiring a signature by the recipient,  postage or delivery charges prepaid, at
the address hereinafter  specified,  or to such other address as the parties may
advise each other in writing from time to time. Any notice shall be addressed as
follows:

     As to IBC:
     Ms. Sara Gomez
     International Bioscience Corporation
     777 South Flagler Drive
     Phillips Point Building
     East Tower, Suite 909
     West Palm Beach, Florida  33401

     With a copy to:
     Joseph L. Raia, Esq.
     Holtzman, Krinzman, Equels & Furia
     2601 South Bayshore Drive, Suite 600
     Miami, Florida  33133

                                       16
<PAGE>
     As to Empyrean:
     Mr. Richard C. Adamany
     Empyrean Bioscience, Inc.
     23800 Commerce Park Road, Suite A
     Cleveland, Ohio  44122

     With a copy to
     Richard H. Kronthal, Esq.
     Kaye, Scholer, Fierman, Hays & Handler, LLP
     425 Park Avenue
     New York, New York   10022

     20. ASSIGNMENT

     (a) Empyrean has the exclusive  right to sub-license  its rights under this
Agreement.

     (b) Neither IBC nor  Empyrean  may assign its rights or delegate its duties
under this Agreement without the express written consent of the other party.

     (c) This  Agreement  shall be  binding  on and inure to the  benefit of the
parties, and their respective legal representatives, successors and assigns.

     (d) No assignment shall be valid unless accepted in writing by the party to
be bound.  Any  assignment  of rights of one party  without the express  written
consent of the other party shall be void, not valid and of no legal effect.

                                       17
<PAGE>
     IN WITNESS  WHEREOF,  the  parties  hereto do hereby  sign,  enter into and
acknowledge this Agreement.

                                        INTERNATIONAL BIOSCIENCE CORPORATION

                                        By:
                                           -------------------------------------

                                        Title:
                                              ----------------------------------

                                        EMPYREAN BIOSCIENCE, INC.

                                        By:
                                           -------------------------------------

                                        Title:
                                              ----------------------------------

                                       18TRADEMARK LICENSE FROM IBC TO EMPYREAN

                     (for sales of Licensed Products in US)

<PAGE>
                     TRADEMARK LICENSE FROM IBC TO EMPYREAN

This License Agreement (the "Agreement") made as of the 9th day of August,  2000
("the  Effective  Date")  by  and  among  INTERNATIONAL  BIOSCIENCE  CORPORATION
("IBC"),  a Florida  corporation,  having an office at 777 South Flagler  Drive,
Phillips Point Building,  East Tower, Suite 909, West Palm Beach, Florida 33401,
and EMPYREAN BIOSCIENCE,  INC.  ("Empyrean"),  a Wyoming corporation,  having an
office at 23800 Commerce Park Road, Suite A, Cleveland, Ohio 44122;

                                WITNESSETH THAT:

     WHEREAS,  IBC  represents  that it is the sole owner of the  entire  right,
title and  interest in and to the Bug  Trademark  (as defined  below),  free and
clear of any liens or encumbrances,  and the entire right, title and interest to
the use of the Bug  Trademark  in  connection  with the  Licensed  Products  (as
defined below);

     WHEREAS,  IBC has granted Empyrean the exclusive right to purchase and sell
Licensed  Products in the United States pursuant to a License Agreement from IBC
to Empyrean executed  concurrently  herewith ("the License Agreement from IBC to
Empyrean");

     WHEREAS, Empyrean desires to acquire the right to use the Bug Trademark (as
defined  below)  on  and  in  connection   with  the   manufacture,   promotion,
merchandising,  distribution  and sale of the  Licensed  Products  in the United
States;

     NOW,  THEREFORE,  in  consideration  of the  premises  and  of  the  mutual
undertakings   hereinafter   set  forth,   and  for  other  good  and   valuable
consideration, IBC and Empyrean hereby agree as follows:
<PAGE>
     1. Definitions

     In this Agreement the following  terms shall have the meanings  hereinafter
specified:

     (a) "Bug Trademark"  shall mean the "GEDA LOGO" used by IBC on all products
based on the Formulation  which is owned by IBC, an exemplar of which is annexed
hereto as Exhibit A.

     (b) "Copyrights" shall mean the copyrights subsisting in the Trade Dress.

     (c)   "Empyrean   Trade   Dress"   shall   mean  the   two-dimensional   or
three-dimensional  packaging  decorations,   designs,  slogans,  tag  lines  and
appliques that are applied to the Licensed Products or packaging therefor.

     (d)  "Formulation"  shall  mean  the  proprietary   formulation  (including
manufacturing  technology and processes) comprising  Benzalkonium Chloride as an
active  ingredient  with  Octoxynol 9 (and  others)  invented and created by Dr.
David  Thornburgh  and  exclusively  owned  by IBC  known  as the  GEDA  line of
products.

     (e) "Gel Product" shall mean the spermicide and  microbicide  contraceptive
gel product  embodying the  Formulation  presently  being developed by IBC, also
known as the GEDA Plus product, designed to prevent the transmission of sexually
transmitted  diseases  including,  but not  limited  to,  gonorrhea,  chlamydia,
syphilis,  Trichomonas,  herpes  I and  II  and  HIV,  and  which  is  presently
undergoing the appropriate and necessary United States  governmental  regulatory
compliance  process to permit  Empyrean  to include  such  product as a Licensed
Product hereunder.

     (f) "Licensed  Products" shall mean products having an effective  amount of
the  Formulation  therein  and  having all  necessary  government  approval  for
commercialization,  including,  but not  limited  to, the Lotion  Products,  Gel
Product and any Derivative Products hereinafter developed by IBC.

                                       2
<PAGE>
     (g)  "Lotion  Products"  (also  known as GEDA  Lotion)  shall mean the hand
sanitizing  lotion presently being  manufactured for Empyrean by Canadian Custom
Packaging  and sold by  Empyrean  as a Licensed  Product,  and  presently  being
marketed by Empyrean under appropriate and necessary United States  governmental
regulatory compliance.

     (h) "Territory" shall mean the United States of America and its possessions
and territories.

     2. REPRESENTATIONS

     IBC represents as follows:

     (a) IBC has the right and authority (i) to enter into this  Agreement,  and
(ii) to grant the License as defined in Section 3 below.

     (b) IBC has executed no agreement in conflict herewith.

     (c) IBC owns all right, title and interest to and in the Bug Trademark,  in
the United States and certain  countries  foreign to the United States,  free of
all liens and encumbrances thereto.

     3. TRADEMARK LICENSE FROM IBC TO EMPYREAN

     (a) IBC hereby  grants to Empyrean,  upon the terms and  conditions of this
Agreement,  whatever rights IBC may have to use the Bug Trademark as part of the
Empyrean Trade Dress in the Territory,  on and in connection with the promotion,
merchandising, distribution and sale of Licensed Products.

     (b) To the extent such Bug Trademark is available for use in the Territory,
Empyrean  agrees to use and shall use the Bug  Trademark in the  Empyrean  Trade
Dress only on or in connection with the promotion,  merchandising,  distribution
and sales of Licensed Products in the Territory.  Empyrean shall not use the Bug

                                       3
<PAGE>
Trademark or sell products using or  incorporating  the Bug Trademark  except as
expressly provided in this Agreement or as approved by IBC.

     (c) IBC  reserves  all  rights to the Bug  Trademark  except  as  expressly
granted herein to Empyrean.

     4. TRADEMARK

     (a)  Empyrean  recognizes  that IBC is the  owner of all  right,  title and
interest in and to the Bug  Trademark in any form or  embodiment  thereof and is
also the owner of the goodwill  attached or which shall  become  attached to the
Bug Trademark in connection with the business and goods in relation to which the
same has been,  is, or shall be used.  Sales by Empyrean shall be deemed to have
been made by IBC for the purposes of goodwill and all uses of the Bug  Trademark
by Empyrean  shall  inure to the benefit of IBC and any rights of IBC.  Empyrean
shall not at any time  intentionally  or  recklessly  do or suffer to be done by
anyone  acting on its behalf or in  connection  with  Empyrean  any act or thing
which will in any way impair the rights of IBC in or to the Bug Trademark or any
application or  registration  thereof or which  depreciates the value of the Bug
Trademark or its reputation.

     (b) Empyrean  shall,  at the request of IBC,  fully  cooperate  with IBC in
preparing,  executing  and  causing  to be  recorded  or filed  such  agreements
(including registered user agreements and other documents reasonably required by
IBC) to confirm the  ownership  by IBC of the Bug  Trademark,  and to  evidence,
protect and  implement  its rights to the Bug  Trademark  within and outside the
Territory  and the  respective  rights  of IBC  and  Empyrean  pursuant  to this
Agreement.  IBC and Empyrean  acknowledge  that only IBC may file and  prosecute
trademark  applications regarding the Bug Trademark or Empyrean's use of the Bug
Trademark  anywhere.  Empyrean will  cooperate  with IBC, at IBC's  request,  in

                                       4
<PAGE>
connection  with  the   preparation,   execution,   filing  and  prosecution  of
applications to register the Bug Trademark both inside and outside the Territory
and the  maintenance  of such  registrations  as may issue.  Upon  expiration or
termination of this Agreement for any reason  whatsoever,  Empyrean will execute
and  file  such  documents  as  shall  be  required  by IBC,  including  without
limitation, termination of any agreements and assignments of rights.

     (c)  Empyrean  shall cause to appear on all  Licensed  Products  and on all
materials on or in connection  with which the Bug Trademark is used such legend,
markings  and notice of any  trademark,  trade name or other  rights  therein or
pertaining  thereto as IBC shall  reasonably  require and shall  comply with all
notice and  marking  requirements  of any law  applicable  or  necessary  to the
protection of the Bug Trademark.

     (d)  Empyrean  shall never (i)  challenge  IBC's  ownership  of or right to
license, or the validity of, the Bug Trademark, any application for registration
thereof or any  trademark  registration  thereof nor (ii)  contest the fact that
Empyrean's rights under this Agreement are solely those of a Licensee.

     (e) At the expiration or termination of this Agreement, except as expressly
provided herein, all rights of Empyrean with respect to use of the Bug Trademark
shall thereupon cease and terminate for all purposes whatsoever.

                                       5
<PAGE>
     5. QUALITY CONTROL

     (a) Empyrean  acknowledges  that the  preservation  and  enhancement of the
value of the Bug Trademark  requires IBC to reasonably  control the type,  image
and quality of products  manufactured  and sold using the Bug  Trademark and the
use of the Bug Trademark in connection with the manufacture and sale of Licensed
Products.

     (b) Empyrean  shall only use the Bug Trademark on the Licensed  Products in
stylization  consistent with and conforming to visual representations and images
to be provided to Empyrean by IBC.

     (c) Empyrean shall submit to IBC for IBC's approval, samples of all labels,
tags,  packaging  and other  materials  intended to be used in  connection  with
Licensed Products,  before the same may be used, and no use shall be made of the
same unless approved by IBC in writing, which approval shall not be unreasonably
withheld.

     (d) In order that IBC may assure itself of the  maintenance  of the quality
standards  set  forth in this  Agreement:

          (i) Before  manufacturing  or having  manufactured for it any Licensed
Products  intended to bear the Bug Trademark,  Empyrean shall deliver to IBC, or
as IBC may direct,  for IBC  approval,  free of charge,  one (1)  pre-production
sample and six (6) production samples related to same, of such Licensed Products
intended  to be sold  by  Empyrean.  Nothing  herein  shall  preclude  IBC  from
requesting additional samples from Empyrean in order to monitor quality control,
and Empyrean shall provide such samples when requested.

          (ii) All Licensed  Products bearing the Bug Trademark  manufactured by
or for  Empyrean or sold,  distributed  or  promoted by it shall  conform in all
material respects to the samples approved by IBC.

                                       6
<PAGE>
     (e) Empyrean shall not use any samples  furnished by IBC, created by or for
Empyrean for use in connection with Licensed Products,  or approved for such use
by IBC, except as provided in this Agreement,  it being the understanding of the
parties  that  Empyrean  may use the same  solely in  connection  with  Licensed
Products.

     (f) Empyrean shall submit to IBC, or as IBC may direct, before publication,
any and all advertising and promotional material for approval by IBC.

     (g) Except as otherwise  expressly  provided  herein,  whenever,  under the
terms of this  Agreement,  the  approval,  consent or permission of IBC shall be
required,  such  approval,  consent  or  permission,  shall not be  unreasonably
withheld or delayed.  If IBC shall deny approval,  it shall state in writing the
reasons therefor.  After any sample,  copy or art work has been approved by IBC,
Empyrean shall not vary or depart  therefrom in any material respect without the
further approval of IBC.

     (h)  Empyrean  agrees  that all  Licensed  Products  will be  manufactured,
labeled,  sold,  distributed,  promoted and  advertised in  accordance  with all
applicable  Federal,  State and  local,  and if  appropriate,  foreign  laws and
regulations.

     (i) Subject to the Bug Trademark requirements set forth herein, the parties
agree that  co-branding the Bug Trademark with the trademark of a third party is
permitted by IBC as long as such third party  trademark  preserves  the value of
the trademark.

     6. INFRINGEMENT OF TRADEMARK

     (a) Empyrean  shall,  promptly after becoming aware of same,  notify IBC of
any infringement or imitation of the Bug Trademark,  of any use by any person or
entity of a trademark or design similar to the Bug  Trademark,  or of any unfair
competition relating to the Bug Trademark, or of any other apparent violation of

                                       7
<PAGE>
the  rights  of IBC,  so as to allow  for IBC to take  such  action as IBC deems
advisable for the protection of IBC's rights.  Empyrean  shall,  if requested by
IBC,  fully  cooperate with IBC and, if so requested by IBC, shall join with IBC
at Empyrean's expense, as a party to any action brought by IBC for such purpose.
In no event,  however,  shall IBC be required to take any action if IBC deems it
inadvisable  to so do. IBC shall have full  control over any action taken by it,
including  without  limitation,  the right to select  counsel,  to settle on any
terms it deems  advisable,  in its  discretion,  to appeal any adverse  decision
rendered in any court,  to discontinue  any action taken by it, and otherwise to
make any decision in respect thereto as it in its discretion deems advisable.

     7. Termination of TRADEMARK LICENSE FROM IBC TO EMPYREAN

     (a) On the  expiration,  or  termination  of this  Agreement or the License
Agreement from IBC to Empyrean,  except as otherwise  expressly provided herein,
all  rights  of  Empyrean   hereunder  shall  terminate   forthwith  and  revert
automatically  to  IBC,  and  neither  Empyrean  nor  its  receivers,  trustees,
representatives,  agents,  successors or assigns shall have any right to exploit
or in any way use the Bug  Trademark  or  Trade  Dress  in  connection  with the
manufacture,  advertising,  merchandising,  promotion,  sale or  distribution of
Licensed  Products  or  otherwise  or any  right to use any  designs,  patterns,
stylings  or samples  furnished  by IBC  created by or for  Empyrean  for use in
connection  with  Licensed  Products or approved by IBC for such use.  Except as
otherwise  expressly provided herein, upon the expiration or termination of this
Agreement  or the  License  Agreement  from  IBC  to  Empyrean,  Empyrean  shall
forthwith  discontinue  all use of the Bug  Trademark  and  Trade  Dress and any
variation or simulation thereof.

                                       8
<PAGE>
     8. TERM

     (a) The term of this Agreement  shall begin on the Effective Date and shall
continue until the  expiration or termination of the License  Agreement from IBC
to Empyrean executed concurrently herewith.

     9. TERMINATION

     (a) IBC shall  have the right to  terminate  this  Agreement  upon  written
notice to  Empyrean  at least  sixty (60) days prior to the end of any  calendar
year, in the event that Empyrean sells no Licensed Products in the Territory for
a period of two (2) years.

     10. Applicable Law

     (a) This  Agreement,  its terms and conditions  and all business  conducted
hereunder  shall be  governed  and  interpreted  under  the laws of the State of
Florida,  without  regard  to  conflict  of laws  provisions.  The  venue of any
arbitration  between the parties arising from or related to this Agreement shall
be in either  Miami-Dade  County or Palm Beach County,  Florida.  Any litigation
arising from or related to this  Agreement  shall be brought  exclusively  in an
appropriate  state or federal court in  Miami-Dade  County or Palm Beach County,
Florida, and the parties waive any right to challenge such venue.

     (b)  Except  for  actions  brought  for  wrongful  termination  or to  seek
termination  of  this  Agreement,  if  any  disagreement  arises  regarding  the
interpretation  of any points of the  Agreement  or any other  point not covered
herein or any claims for damages or specific performance, the disagreement, upon
request of either party hereto delivered in writing to the other party, shall be
resolved  by  arbitration  before a single  arbitrator  in  accordance  with the
commercial   rules  and  procedures  set  forth  by  the  American   Arbitration
Association. The prevailing party in any litigation or arbitration brought under

                                       9
<PAGE>
this  Agreement  shall be entitled  to recover  reasonable  attorney's  fees and
costs.

     (c) In the  event  any  provision  of this  Agreement  shall  be held to be
invalid,  illegal or  unenforceable,  the  remaining  terms shall remain in full
force and effect,  to effectuate  this Agreement in accordance  with its intent.
Headings, title and subtitles of this Agreement are for convenience of reference
only and are not to be considered in construing the terms of this Agreement.

     11. Sole and Complete Agreement

     (a) This  Agreement  is the sole and  complete  statement of the parties of
their rights and  obligations  with respect to the subject matter  hereof.  This
Agreement is an  integrated  agreement and replaces and  supersedes  any and all
previous obligations and agreements between the parties,  their predecessors and
subsidiaries, both oral and written. The Parties hereto recognize and agree that
no  representations  or  warranties  have been made  except as set forth in this
Agreement. Except as may otherwise be expressly provided herein, by signing this
Agreement  the parties  expressly  release each other,  their  predecessors  and
subsidiaries from any and all existing  obligations that pre-date this Agreement
as if such obligations  have been fully performed and satisfied.  Any amendments
to this Agreement shall be in writing and executed by both parties hereto.

     12. Notices

     (a)  All  notices,  requests,  demands,  instructions,  consents  or  other
communications  required or permitted to be given under this Agreement  shall be
in  writing  and  shall be  deemed  to have  been  duly  given if (i)  delivered
personally,  (ii) mailed  postage  prepaid by  certified  mail,  return  receipt

                                       10
<PAGE>
requests,  (iii)  sent  by  a  nationally  recognized  express  courier  service
requiring a signature by the recipient,  postage or delivery charges prepaid, at
the address hereinafter  specified,  or to such other address as the parties may
advise each other in writing from time to time. Any notice shall be addressed as
follows:

     As to Empyrean:
     Mr. Richard C. Adamany
     Empyrean Bioscience, Inc.
     23800 Commerce Park Road, Suite A
     Cleveland, Ohio  44122

     With a copy to
     Richard H. Kronthal, Esq.
     Kaye, Scholer, Fierman, Hays & Handler, LLP
     425 Park Avenue

     New York, New York   10022

     As to IBC:
     Ms. Sarah Gomez

     International Bioscience Corporation
     777 South Flagler Drive
     Phillips Point Building

     East Tower, Suite 909
     West Palm Beach, Florida  33401

     With a copy to:
     Joseph L. Raia, Esq.
     Holtzman, Krinzman, Equels & Furia
     2601 South Bayshore Drive, Suite 600
     Miami, Florida  33133

     13. Assignment

     (a) Empyrean has no right to sub-license or otherwise assign its rights and
delegate its duties under this Agreement.

     (b) Neither IBC nor  Empyrean  may assign its rights or delegate its duties
under this Agreement without the express written consent of the other party.

                                       11
<PAGE>
     (c) This  Agreement  shall be  binding  on and inure to the  benefit of the
parties, and their respective legal representatives, successors and assigns.

     (d) No assignment shall be valid unless accepted in writing by the party to
be bound.  Any  assignment  of rights of one party  without the express  written
consent of the other party shall be void, not valid and of no legal effect.

                                       12
<PAGE>
     IN WITNESS  WHEREOF,  the  parties  hereto do hereby  sign,  enter into and
acknowledge this Agreement.

                                        INTERNATIONAL BIOSCIENCE CORPORATION

                                        By: ____________________________________

                                        Title: _________________________________

                                        EMPYREAN BIOSCIENCE, INC.

                                        By: ____________________________________

                                        Title: _________________________________

                                       13
<PAGE>
                                    EXHIBIT A

                                     GEDA(R)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]